Kezar Life Sciences (NASDAQ:KZR) Trading Up 7.5%

Kezar Life Sciences Inc (NASDAQ:KZR)’s share price was up 7.5% on Friday . The company traded as high as $7.95 and last traded at $7.71. Approximately 642,139 shares traded hands during mid-day trading, an increase of 518% from the average daily volume of 103,883 shares. The stock had previously closed at $7.17.

A number of analysts have weighed in on KZR shares. Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Saturday, March 16th. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a report on Tuesday, March 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Kezar Life Sciences has an average rating of “Buy” and an average target price of $24.33.

The company has a debt-to-equity ratio of 0.06, a quick ratio of 21.81 and a current ratio of 21.81. The stock’s fifty day simple moving average is $12.56.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, equities analysts anticipate that Kezar Life Sciences Inc will post -2.04 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Kezar Life Sciences by 131,900.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,640 shares of the company’s stock worth $47,000 after acquiring an additional 2,638 shares during the period. BB Biotech AG bought a new position in shares of Kezar Life Sciences during the 4th quarter worth about $19,315,000. BlackRock Inc. lifted its holdings in shares of Kezar Life Sciences by 1.9% during the 4th quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Kezar Life Sciences by 126.7% during the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares during the period. Finally, Spark Investment Management LLC lifted its holdings in shares of Kezar Life Sciences by 125.3% during the 1st quarter. Spark Investment Management LLC now owns 21,200 shares of the company’s stock worth $376,000 after acquiring an additional 11,790 shares during the period. 51.88% of the stock is owned by institutional investors.

About Kezar Life Sciences (NASDAQ:KZR)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: What impact do institutional investors have on markets?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.